Patents Assigned to New York Blood Center, Inc.
  • Publication number: 20050070501
    Abstract: A soft, pliable cellulose acetate phthalate (CAP)—hydroxypropyl cellulose (HPC) composite film is provided which is generated by casting from organic solvent mixtures containing ethanol. The film rapidly reduces the infectivity of several sexually transmitted disease pathogens, including the human immunodeficiency virus (HIV-1), herpesvirus (HSV), non-viral sexually transmitted disease pathogens (such as Neisseria gonorrhoeae, Haemophilus ducreyi, Chlamydia trachomatis and Treponema pallidum) and bacteria associated with bacterial vaginosis (BV). The film is converted into a gel/cream and thus does not have to be removed following application and use. In addition to being a topical microbicide, the film can be employed for the mucosal delivery of pharmaceuticals other than cellulose acetate phthalate.
    Type: Application
    Filed: August 16, 2004
    Publication date: March 31, 2005
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Patent number: 6838240
    Abstract: The present invention provides a method for diagnosing Bloom's syndrome (BS) as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a human subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: January 4, 2005
    Assignees: New York Blood Center, Inc., University of Cincinnati
    Inventors: Nathan Ellis, James German, Joanna Groden
  • Patent number: 6727240
    Abstract: A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: April 27, 2004
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander R. Neurath, Shibo Jiang, Asim Kumar Debnath
  • Patent number: 6723322
    Abstract: The present invention provides a method for inducing angiogenesis in a tissue, by contacting the tissue with an amount of Ov-ASP effective to induce angiogenesis in the tissue. The present invention further provides a method for screening for an anti-Ov-ASP factor, by contacting a factor of interest with Ov-ASP, and assessing the ability of the factor to inhibit angiogenic activity of Ov-ASP. Additionally, the present invention provides a method for inhibiting angiogenesis in a subject.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: April 20, 2004
    Assignees: New York Blood Center, Inc., Case Western Reservei University, UAB Research Foundation
    Inventors: Sara Lustigman, Eric Pearlman, Thomas R. Unnasch
  • Patent number: 6670123
    Abstract: The present invention provides an isolated nucleic acid encoding KIAA0918, an isolated nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to a nucleic acid encoding KIAA0918, a purified KIAA0918 protein, a purified protein encoded by a nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to a nucleic acid encoding KIAA0918, a method of making KIAA0918 protein, an antibody specific for KIAA0918, a method for producing an antibody specific for KIAA0918 protein, a vector comprising a nucleic acid encoding KIAA0918, and a host cell transformed with a vector comprising a nucleic acid encoding KIAA0918. Also provided are methods for detecting the presence of and isolating hematopoietic stem cells in a heterogeneous cell suspension and for assessing gene expression in a tissue sample.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: December 30, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Belyavsky, Sergey Shmelkov, Jan Visser
  • Patent number: 6610501
    Abstract: The present invention provides a porcine antigen that binds to human xenoreactive antibodies. The porcine antigen differs from the known porcine xenoantigens in that the antigen does not include an &agr;Gal epitope. The present invention also provides methods to purify the porcine antigen of the invention, as well as agents that bind to the antigen. The antigen may be used to generate antibodies against the antigen. The antigen is useful for detecting the presence of human xenoreactive antibodies against the antigen in blood and blood compositions, and antibodies against the antigen may be used to detect the presence of the antigen in samples. The invention also provides methods and pharmaceutical compositions for reducing a host rejection response to a porcine xenograft. Finally, a method to treat human blood or blood-derived compositions to reduce the level of human xenoantibodies is disclosed.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: August 26, 2003
    Assignee: New York Blood Center, Inc.
    Inventor: Alex Zhu
  • Patent number: 6607914
    Abstract: The present invention provides a purified and isolated nucleic acid encoding a camello protein. The present invention also provides a vector comprising nucleic acid encoding camello, a host cell transformed with the vector, and a method for producing recombinant camello protein. In addition, the present invention also provides a purified camello protein. Also provided by the present invention is nucleic acid probes and mixtures thereof specific for camello nucleic acid and antibodies immunoreactive with camello. The present invention also provides a methods for screening for agents which bind to the camello protein and the nucleic acid encoding the camello. Finally, the present invention provides a non-human, transgenic model for camello expression.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: August 19, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander V. Belyavsky, Natalia N. Luchinskaya, Anna E. Popsueva
  • Patent number: 6596297
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one pectin, such as an apple pectin, and optionally at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: July 22, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick
  • Patent number: 6596497
    Abstract: A method for the screening of antiviral compounds targeted to the HIV gp41 core structure comprising capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer containing an N-peptide and a C-peptide onto a solid-phase, mixing a compound to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixture to the resultant polyclonal antibody coated solid-phase and then removing unbound peptides and unbound compound, adding a monoclonal antibody directed against the trimer of a heterodimer containing an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: July 22, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Asim K. Debnath
  • Patent number: 6572875
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: June 3, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick
  • Patent number: 6541229
    Abstract: Disclosed is an improved process for irradiating cell-containing compositions, especially, red cell-containing compositions, wherein vitamin E or a derivative thereof is added to the cell-containing composition prior to, during or after such irradiation. Addition of vitamin E or a derivative thereof is protective of cells in such compositions, but not of virus. Cells irradiated using the inventive process show a reduced leakage of K+ from cells and also a reduced loss of negative charges from the cell membrane compared to cells subjected to the similar process wherein vitamin E or a derivative thereof are not used. In addition, red blood cells sterilized by this process are better preserved during storage and their life-time in the circulation in vivo is greatly enhanced.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: April 1, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Ehud Ben-Hur, Shanti Rywkin, Bernard Horowitz
  • Publication number: 20030017490
    Abstract: A method of identification of differentially expressed messenger RNA (mRNA) which consists of synthesizing from a set of sequences of mRNA sets of fragments of complementary DNA (cDNA), which are separated with the aid of gel electrophoresis and the pictures of separation of the cDNA from different types of cells are compared and fragments with differential signal intensity are identified. For formation of the set of fragments the cDNA is cleaved with the aid of restriction nucleases. A method of cloning of differentially expressed mRNAs consists of synthesizing from sets of sequences of mRNAs from different types of cells sets of fragments of complementary DNA (cDNA) which are separated with the aid of gel electrophoresis, the pictures of the separation of the cDNA from different types of cells are compared, fragments of cDNA with different signal intensities are separated from the gel, amplified with the aid of a polymerase chain reaction and cloned to a plasmid or phage vector.
    Type: Application
    Filed: June 18, 2002
    Publication date: January 23, 2003
    Applicant: New York Blood Center Inc.
    Inventors: Alexander V. Belyavsky, Natalia B. Ivanova
  • Patent number: 6491678
    Abstract: A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: December 10, 2002
    Assignee: New York Blood Center, Inc.
    Inventors: Pablo Rubinstein, Philip Henry Coelho, Cladd E. Stevens
  • Patent number: 6462030
    Abstract: A method for treating or preventing bacterial vaginosis comprising administering to a human female an effective anti-bacterial vaginosis amount of a composition comprising at least one active compound selected from the group consisting of cellulose acetate phthalate and hydroxypropyl methylcellulose phthalate, either alone or in combination with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: October 8, 2002
    Assignee: New York Blood Center, Inc.
    Inventor: Alexander R. Neurath
  • Publication number: 20020127276
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose; or a pectin, such as an apple pectin. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Application
    Filed: March 5, 2002
    Publication date: September 12, 2002
    Applicant: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick
  • Patent number: 6413714
    Abstract: The present invention concerns a process for inactivating extracellular and intracellular virus in a biological composition without incurring substantial disruption or inactivation thereof, said process comprising subjecting said composition to a virucidally effective amount of UVA1 irradiation substantially in the absence of UVA2 irradiation for a period of time sufficient to thereby inactivate said virus while retaining functionality of said composition. The biological composition is advantageously a product that contains red blood cells or platelets. The process is advantageously carried out in the presence of an irradiation sensitizer compound and/or a quencher. The present invention also concerns the product substantially identical to that produced by the inventive process.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: July 2, 2002
    Assignee: New York Blood Center, Inc.
    Inventors: Henrietta Margolis-Nunno, Ehud Ben-Hur, Bernard Horowitz
  • Publication number: 20020076430
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Application
    Filed: September 28, 2001
    Publication date: June 20, 2002
    Applicant: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick
  • Patent number: 6365145
    Abstract: The present invention provides a method for removing hair from a selected skin area comprising the steps of (a) applying a liposome composition comprising a photosensitizer to the selected skin area so that the composition is introduced into hair follicle ducts of the skin area, wherein the photosensitizer is present in the composition in an amount effective to undergo a reaction and damage the hair follicles upon application to the skin area of light at an appropriate wavelength, energy and duration to penetrate the skin and activate the photosensitizer; (b) removing from the skin area substantially all of the liposome composition which is not introduced into the hair follicle ducts; and (c) applying light to the skin area at an appropriate wavelength, energy and duration to penetrate the skin and cause the photosensitizer to undergo a reaction to damage the hair follicles. The present invention also provides a composition useful for hair removal.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: April 2, 2002
    Assignee: New York Blood Center, Inc.
    Inventors: Ehud Ben-Hur, Maria M. Zuk, Wai-Shun Chan
  • Patent number: 6348453
    Abstract: The present invention provides a method for treating a viral infection in a subject in need of such treatment comprising administering to the subject a photosensitizer formulated in a liposome carrier, and exposing the subject to light at a wavelength 20-40 nm greater than the maximum absorption of the photosensitizer at a sufficient dose and duration to treat the viral infection in the subject. The present invention also provides a method for treating a viral infection in a subject in need of such treatment comprising administering to the subject (i) a photosensitizer formulated in a liposome carrier and (ii) at least one quencher, and exposing the subject to light at a sufficient wavelength, dose and duration to treat the viral infection in the subject.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: February 19, 2002
    Assignee: New York Blood Center, Inc.
    Inventor: Ehud Ben-Hur
  • Patent number: 6323012
    Abstract: The present invention provides a method for treating a viral infection in a subject. The method comprises administering to the subject an amount of 5-aminolevulinic acid to cause virus-infected cells to accumulate protoporphyrin in amounts such that upon application of a sufficient dose of red light, the virus-infected, protoporphyrin-accumulated cells will be destroyed; and applying a sufficient dose of red light to the virus-infected, protoporphyrin-accumulated cells to destroy the virus-infected, protoporphyrin-accumulated cells.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: November 27, 2001
    Assignees: New York Blood Center, Inc., Bar-Ilan University
    Inventors: Ehud Ben-Hur, Zvi Malik